Progentos Therapeutics
Pre-clinicalProgentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
Founded
2021
Focus
Small Molecules
About
Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
Funding History
2Total raised: $77M
Series A$65MForbionMay 15, 2023
Seed$12MDementia Discovery FundAug 15, 2021
Company Info
TypePrivate
Founded2021
LocationCambridge, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile